Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.

Purpose: Naloxegol, an oral once-daily peripherally acting mu-opioid receptor antagonist, is indicated for the treatment of opioid-induced constipation (OIC) with inadequate response to laxative(s), in cancer and non-cancer patients. This study mainly aimed to assess in real-life conditions the efficacy and safety of naloxegol in cancer pain patients and the evolution of their quality of life.

Methods: A non-interventional, 4-week follow-up study was conducted in 24 French oncology and pain centers between 2018 and 2019.

[General characteristics of the new oral anticoagulants].

Treatment with vitamin K antagonists are subject to a common iatrogenic mainly characterized by hemorrhagic stroke. Their narrow therapeutic range associated with variability largely explains this phenomenon. New oral anticoagulants (NOAC) are now available.